ESPR – esperion therapeutics, inc. (US:NASDAQ)
Stock Stats
News
12/18
08:03 am
espr
High
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $4.00 price target on the stock.
12/18
07:00 am
espr
High
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
12/17
08:54 am
espr
Low
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
12/13
12:42 pm
espr
Medium
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
12/13
06:00 am
espr
High
Esperion Announces $210 Million Convertible Debt Financing
11/7/2024
06:00 am
ESPR
-4.5%
MISS
8/12/2024
06:00 am
ESPR
-17.5%
MISS
5/7/2024
06:00 am
ESPR
7.7%
BEAT
2/27/2024
06:00 am
ESPR
5.8%
BEAT
12/18
04:58 am
Reinstates
Neutral
Goldman Sachs
High
-12.9%
12/18
04:58 am
Reinstates
Neutral
Goldman Sachs
High
-12.9%
12/18
04:58 am
Reinstates
Neutral
Goldman Sachs
High
-12.9%
12/17
08:54 am
Initiates
Overweight
Cantor Fitzgerald
Low
1.7%
12/17
08:39 am
Initiates
Overweight
Wedbush
Low
2.1%
12/18
04:15 pm
espr
Low
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Halladay Benjamin
12/18
04:14 pm
espr
Low
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Warren Eric
12/18
04:13 pm
espr
Low
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Koenig Sheldon L.
12/18
07:11 am
espr
High
Form 8-K Esperion Therapeutics, For: Dec 17
12/17
03:46 pm
espr
Low
Form 144 Esperion Therapeutics, Filed by: Warren Eric
Show more
Top News Gainers
3/18 Form 8-K Esperion Therapeutics, For: Mar 14 18.2%
3/17 Esperion Therapeutics Inc (NASDAQ: ESPR) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 14.6%
5/5 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review 11.6%
11/17 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions 10.0%
4/20 Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan 7.2%
1/31 Form 8-K Esperion Therapeutics, For: Jan 31 6.6%
2/12 Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC 5.9%
2/28 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5.2%
4/16 Form DEF 14A Esperion Therapeutics, For: May 28 4.6%
3/23 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol 4.5%
Top News Decliners
2/27 Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results -11.2%
3/12 Form 4 Esperion Therapeutics, For: Mar 11 Filed by: MAYLEBEN TIMOTHY M -10.3%
4/1 Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a price target on the stock. -9.3%
11/6 Q3/2019 9/30/2019 EPS -2.520 ZacksConsensus -2.010 ActVsEst (0.510) - Miss -8.6%
3/31 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.9%
4/30 Esperion to Report First Quarter 2020 Financial Results May 6, 2020 -7.9%
1/24 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.3%
2/25 Esperion Therapeutics: The Path After FDA Approval [Seeking Alpha] -4.8%
8/30 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.7%
2/14 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. -4.5%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3